Business Description GENBIOMA offers a groundbreaking solution. We develop a personalised microbiome-based platform targeting type 2 diabetes (T2D), pre-diabetes (PreD), and gestational diabetes (GestD) through innovative probiotic and postbiotic formulations, harnessing the power of proprietary bacterial strains pA1c™ and pA2c™. Affordable probiotic and postbiotics that can revert blood sugar levels to normal with just one daily dose. Stable, safe, and natural nutritonal ingredientes and supplements complementary to diet and medication, with the potential to reduce T2D-associated healthcare expenses.
Our business strategy is to operate within a B2B framework spanning the pharma and food sectors.
Probiotics, Postbiotics & Microbial Metabolites for Metabolic Disorders
Genbioma is a biotechnology company devoted to Microbiome Study for metabolic health.
A breakthrough in MICROBIOTA SCIENCE to specifically design PREMIUM PROBIOTICS & POSTBIOTICS based on targeted strains that help to MANAGE METABOLISM to improve HUMAN HEALTH.
Genbioma´s innovative capacity has been internationally rewarded with PROBIOTA PIONEERS 2022.
Long Business Description Genbioma is a biotechnology company devoted to the development and commercialisation of next-generation probiotic strains & postbiotic ingredients, with a focus on metabolic health applications.
The technology is focused on an emerging field of research on Probiotics & Postbiotics to balance the gut microbiota and improve health.
Solid scientific research on the Mechanism of Action to regulate Metabolism & Gut Microbiota.
Probiotic & Postbiotic Solutions for the nutritional management of glucose and lipid metabolic disorders related to Diabetes, Dyslipemias & Obesity.
Property Probiotic pA1c® and Postbiotic pA1c®HI to regulate blood sugar levels by modifying the gut microbiota composition.
Tags Microbiome, Probiotics, Metabolic Health, Diabetes
